breast cancer biomarkers

Release time ：Dec-21,2024

Breast cancer biomarkers are specific proteins or molecules identified within the bodies of individuals with breast cancer. They serve critical roles in diagnosing the disease, forecasting its progression, evaluating responses to treatment, and monitoring for recurrence. The identification of these biomarkers assists physicians in gaining a deeper understanding of a patient's condition and in devising personalized treatment strategies.

Commonly recognized breast cancer biomarkers encompass the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and the Ki-67 index. The outcomes of testing for these biomarkers can inform physicians on the most suitable therapeutic approaches, including endocrine therapy and targeted therapy. Additionally, emerging biomarkers under investigation, such as mutations in the BRCA1/2 genes and PIK3CA mutations, may become pivotal in the management of breast cancer in the future.

Understanding the results of their biomarker testing is crucial for breast cancer patients. This knowledge not only aids in a better comprehension of their disease but also empowers them to engage in treatment decision-making. Patients should vigilantly monitor their health status, engage in regular check-ups and follow-up consultations to promptly identify and address any emerging issues. Throughout the treatment journey, patients are advised to adhere to their physicians' recommendations, to strategically plan their treatment in pursuit of optimal therapeutic outcomes.